- ►diabetesjournals.org M Saraheimo, C Forsblom, L Thorn, J Wadén, M … - Diabetes care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This was a prospective follow-up study as a part
of the nationwide Finnish Diabetic Nephropathy Study; 1,330 type 1 diabetic
patients were followed for 5.0 ± 2.2 years. Patients were divided at ... Cited by 9 - Related articles - BL Direct - All 8 versions
- ►critcaremed.org F Montecucco, F Mach - Rheumatology, 2009 - Br Soc Rheumatology RA is characterized by a systemic inflammatory state, in which immune cells and
soluble mediators play a crucial role. These inflammatory processes resemble
those in other chronic inflammatory diseases, such as atherosclerosis. The ... Cited by 9 - Related articles - All 10 versions
- ►nursing2008.com M Hanefeld - Diabetes, obesity & metabolism, 2009 - pt.wkhealth.com Pioglitazone, a thiazolidinedione, has established efficacy in improving
glycaemic control in patients with type 2 diabetes. Pioglitazone also improves
components of the mixed dyslipidaemia profile common in these patients, as ... Cited by 1 - Related articles - All 6 versions
M Fisher, GR Infirmary, UK Glasgow - International Journal of Clinical Practice, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Related articles - All 3 versions
M Hanefeld - Diabetes, Obesity and Metabolism, 2009 - pt.wkhealth.com Pioglitazone, a thiazolidinedione, has established efficacy in improving
glycaemic control in patients with type 2 diabetes. Pioglitazone also improves
components of the mixed dyslipidaemia profile common in these patients, as ...
K Papathanassiou, KK Naka, N Kazakos, C … - Atherosclerosis, 2009 - Elsevier The 2 groups did not differ in age (mean ± SD, 63.6 ± 7.3 years vs 62.8 ± 7.2
years respectively), or any measured variable at baseline. Fasting glucose and
glycated haemoglobin improved similarly in both groups. There were ... Related articles - All 43 versions
MS MD, CF MD, LT MD, JW MD, MRB MD, OH … - Am Diabetes Assoc M. Saraheimo MD1,2, C. Forsblom MD, DMSC1,2, L. Thorn MD1,2, J. Wadén MD1,2, M.
Rosengård-Bärlund MD1,2, O. Heikkilä MD1,2, K. Hietala MD1, D. Gordin MD2, J.
Frystyk MD, DMSC, PHD3, A. Flyvbjerg MD, DMSC3, P.-H. Groop MD, DMSC1,2 on ... Related articles
M Saraheimo - oa.doria.fi ACADEMIC DISSERTATION To be presented, with permission of the Medical Faculty of
the University of Helsinki, For public examination in Auditorium 2, Biomedicum
Helsinki, Haartmaninkatu 8, On November 14th, at 12 noon. View as HTML
C Clar, P Royle, N Waugh, 2009 - pubmedcentral.nih.gov Medline, Embase, and the Cochrane Library were searched for randomised
controlled trials comparing pioglitazone in combination with any
insulin-containing regimen in comparison with the same insulin regimen ... Related articles - All 9 versions
A Hartemann-Heurtier, M Halbron, JL Golmard, … - Diabetes Research and Clinical Practice, 2009 - Elsevier Insulin and pioglitazone resulted in a significant decrease in HbA1c (−1.6%
and −1.2%, respectively) and a significant increase in total body fat mass (1
± 2.3 and 3.3 ± 2.7 kg, respectively). There was no change in IAF content ... Related articles - All 4 versions
